Dilation of porcine retinal arterioles to cilostazol: Roles of eNOS phosphorylation via cAMP/protein kinase A and AMP-activated protein kinase and potassium channels

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 2, 2013, Pages 1443-1449

  Tanano, Ichiro ^a   Nagaoka, Taiji ^a   Omae, Tsuneaki ^a   Ishibazawa, Akihiro ^a   Kamiya, Takayuki ^a   Ono, Shinji ^a   Yoshida, Akitoshi ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CILOSTAZOL; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; NITROPRUSSIDE SODIUM; POTASSIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DIAMETER; CONTROLLED STUDY; ENDOTHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETINA BLOOD VESSEL; SIGNAL TRANSDUCTION; SWINE; VASODILATATION; VASOMOTOR REFLEX; VIDEO MICROSCOPY;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ARTERIOLES; CYCLIC AMP; DISEASE MODELS, ANIMAL; FEMALE; MALE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; POTASSIUM CHANNELS; RETINAL VESSELS; SWINE; TETRAZOLES; VASODILATION; VASODILATOR AGENTS;

EID: 84874969761     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10115     Document Type: Article

References (54)

1. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F. Cilostazol as a unique antithrombotic agent. Curr Pharm Des. 2003;9:2289-2302.
2. Uchiyama S, Demaerschalk BM, Goto S, et al. Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials. J Stroke Cerebrovasc Dis. 2009;18:482-490.
3. Shinohara Y, Gotoh F, Tohgi H, et al. Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis. 2008;26:63-70.
4. Shinoda-Tagawa T, Yamasaki Y, Yoshida S, et al. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with type II diabetes. Diabetologia. 2002;45:188-194.
5. Nagaoka T, Sato E, Takahashi A, Yokota H, Sogawa K, Yoshida A. Impaired retinal circulation in patients with type 2 diabetes mellitus: retinal laser Doppler velocimetry study. Invest Ophthalmol Vis Sci. 2010;51:6729-6734.
6. Suzuki M, Harino S, Kitanishi K. Effects of intravenous cilostazol on optic nerve head and choroidal blood flow in anesthetized cats. J Ocul Pharmacol Ther. 1998;14:239-245.
7. Hotta H, Ito H, Kagitani F, Sato A. Cilostazol, a selective cAMP phosphodiesterase inhibitor, dilates retinal arterioles and increases retinal and choroidal blood flow in rats. Eur J Pharmacol. 1998;344:49-52.
8. Hein TW, Yuan Z, Rosa RH Jr, Kuo L. Requisite roles of A2A receptors, nitric oxide, and KATP channels in retinal arteriolar dilation in response to adenosine. Invest Ophthalmol Vis Sci. 2005;46:2113-2119.
9. Hein TW, Xu W, Kuo L. Dilation of retinal arterioles in response to lactate: role of nitric oxide, guanylyl cyclase, and ATPsensitive potassium channels. Invest Ophthalmol Vis Sci. 2006;47:693-699.
10. Nagaoka T, Hein TW, Yoshida A, Kuo L. Simvastatin elicits dilation of isolated porcine retinal arterioles: role of nitric oxide and mevalonate-rho kinase pathways. Invest Ophthalmol Vis Sci. 2007;48:825-832.
11. Omae T, Nagaoka T, Tanano I, Yoshida A. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, induces dilation of isolated porcine retinal arterioles: role of nitric oxide and potassium channels. Invest Ophthalmol Vis Sci. 2011;52:6749-6756.
12. Kuo L, Davis MJ, Chilian WM. Endothelium-dependent, flowinduced dilation of isolated coronary arterioles. Am J Physiol. 1990;259:H1063-H1070.
13. Hein TW, Kuo L. cAMP-independent dilation of coronary arterioles to adenosine: role of nitric oxide, G proteins, and K(ATP) channels. Circ Res. 1999;85:634-642.
14. Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev. 1978;30:293-331.
15. Earley S, Pastuszyn A, Walker BR. Cytochrome p-450 epoxygenase products contribute to attenuated vasoconstriction after chronic hypoxia. Am J Physiol Heart Circ Physiol. 2003;285:H127-H136.
16. Burnham MP, Bychkov R, Feletou M, et al. Characterization of an apamin-sensitive small-conductance Ca(2{thorn})-activated K({thorn}) channel in porcine coronary artery endothelium: relevance to EDHF. Br J Pharmacol. 2002;135:1133-1143.
17. Bychkov R, Burnham MP, Richards GR, et al. Characterization of a charybdotoxin-sensitive intermediate conductance Ca2{thorn}activated K{thorn} channel in porcine coronary endothelium: relevance to EDHF. Br J Pharmacol. 2002;137:1346-1354.
18. Stankevicius E, Dalsgaard T, Kroigaard C, et al. Opening of small and intermediate calcium-activated potassium channels induce relaxation mainly mediated by NO release in large arteries and EDHF in small arteries from rat. J Pharmacol Exp Ther. 2011;339:842-850.
19. Hein TW, Wang W, Zoghi B, Muthuchamy M, Kuo L. Functional and molecular characterization of receptor subtypes mediating coronary microvascular dilation to adenosine. J Mol Cell Cardiol. 2001;33:271-282.
20. Thors B, Halldorsson H, Jonsdottir G, Thorgeirsson G. Mechanism of thrombin mediated eNOS phosphorylation in endothelial cells is dependent on ATP levels after stimulation. Biochim Biophys Acta. 2008;1783:1893-1902.
21. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol. 1995;268:C799-C822.
22. Nagaoka T, Hein TW, Yoshida A, Kuo L. Resveratrol, a component of red wine, elicits dilation of isolated porcine retinal arterioles: role of nitric oxide and potassium channels. Invest Ophthalmol Vis Sci. 2007;48:4232-4239.
23. Lee YC, Chang HH, Liu CH, et al. Methyl palmitate: a potent vasodilator released in the retina. Invest Ophthalmol Vis Sci. 2010;51:4746-4753.
24. Stewart M, Needham M, Bankhead P, et al. Feedback via Ca(2)({thorn})-activated ion channels modulates endothelin 1 signaling in retinal arteriolar smooth muscle. Invest Ophthalmol Vis Sci. 2012;53:3059-3066.
25. Goirand F, Solar M, Athea Y, et al. Activation of AMP kinase alpha1 subunit induces aortic vasorelaxation in mice. J Physiol. 2007;581:1163-1171.
26. Morrow VA, Foufelle F, Connell JM, Petrie JR, Gould GW, Salt IP. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J Biol Chem. 2003;278:31629-31639.
27. Akiyama H, Kudo S, Shimizu T. The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man. Arzneimittelforschung. 1985;35:1124-1132.
28. Nakamura K, Ikomi F, Ohhashi T. Cilostazol, an inhibitor of type 3 phosphodiesterase, produces endothelium-independent vasodilation in pressurized rabbit cerebral penetrating arterioles. J Vasc Res. 2006;43:86-94.
29. Yashiro Y, Ohhashi T. Effects of cilostazol, a selective cyclic AMP phosphodiesterase inhibitor on isolated rabbit spinal arterioles. Jpn J Physiol. 2002;52:471-477.
30. Birk S, Edvinsson L, Olesen J, Kruuse C. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries. Eur J Pharmacol. 2004;489:93-100.
31. Nakamura T, Houchi H, Minami A, et al. Endotheliumdependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta. Life Sci. 2001;69:1709-1715.
32. Hashimoto A, Miyakoda G, Hirose Y, Mori T. Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/ protein kinase A-and phosphatidylinositol 3-kinase/Aktdependent mechanism. Atherosclerosis. 2006;189:350-357.
33. Suzuki K, Uchida K, Nakanishi N, Hattori Y. Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes. Am J Hypertens. 2008;21:451-457.
34. Stankevicius E, Kevelaitis E, Vainorius E, Simonsen U. Role of nitric oxide and other endothelium-derived factors [in Lithuanian]. Medicina (Kaunas). 2003;39:333-341.
35. Hein TW, Liao JC, Kuo L. oxLDL specifically impairs endothelium-dependent, NO-mediated dilation of coronary arterioles. Am J Physiol Heart Circ Physiol. 2000;278:H175-H183.
36. Dalsgaard T, Kroigaard C, Bek T, Simonsen U. Role of calciumactivated potassium channels with small conductance in bradykinin-induced vasodilation of porcine retinal arterioles. Invest Ophthalmol Vis Sci. 2009;50:3819-3825.
37. Busse R, Edwards G, Feletou M, Fleming I, Vanhoutte PM, Weston AH. EDHF: bringing the concepts together. Trends Pharmacol Sci. 2002;23:374-380.
38. Li L, Bressler B, Prameya R, Dorovini-Zis K, Van Breemen C. Agonist-stimulated calcium entry in primary cultures of human cerebral microvascular endothelial cells. Microvasc Res. 1999; 57:211-226.
39. Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J Pharmacol Exp Ther. 2001;299:818-824.
40. Huang PL. eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab. 2009;20:295-302.
41. Gray DW, Marshall I. Novel signal transduction pathway mediating endothelium-dependent beta-adrenoceptor vasorelaxation in rat thoracic aorta. Br J Pharmacol. 1992;107:684-690.
42. Schafer A, Burkhardt M, Vollkommer T, et al. Endotheliumdependent and-independent relaxation and VASP serines 157/ 239 phosphorylation by cyclic nucleotide-elevating vasodilators in rat aorta. Biochem Pharmacol. 2003;65:397-405.
43. Miyoshi H, Nakaya Y. Calcitonin gene-related peptide activates the K{thorn}channels of vascular smooth muscle cells via adenylate cyclase. Basic Res Cardiol. 1995;90:332-336.
44. Schubert R, Serebryakov VN, Engel H, Hopp HH. Iloprost activates KCa channels of vascular smooth muscle cells: role of cAMP-dependent protein kinase. Am J Physiol. 1996;271: C1203-C1211.
45. Chen ZP, Mitchelhill KI, Michell BJ, et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett. 1999;443:285-289.
46. Hardie DG, Scott JW, Pan DA, Hudson ER. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett. 2003;546:113-120.
47. Ford RJ, Rush JW. Endothelium-dependent vasorelaxation to the AMPK activator AICAR is enhanced in aorta from hypertensive rats and is NO and EDCF dependent. Am J Physiol Heart Circ Physiol. 2011;300:H64-H75.
48. Omae T, Nagaoka T, Tanano I, Kamiya T, Yoshida A. Fenofibrate, an anti-dyslipidemia drug, elicits the dilation of isolated porcine retinal arterioles: role of nitric oxide and AMP-activated protein kinase. Invest Ophthalmol Vis Sci. 2012;53:2880-2886.
49. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399: 601-605.
50. Fulton D, Gratton JP, McCabe TJ, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399:597-601.
51. Fleming I. Molecular mechanisms underlying the activation of eNOS. Pflugers Arch. 2010;459:793-806.
52. Murakami H, Murakami R, Kambe F, et al. Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochem Biophys Res Commun. 2006;341:973-978.
53. Davis BJ, Xie Z, Viollet B, Zou MH. Activation of the AMPactivated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes. 2006;55:496-505.
54. Okamoto N, Ito Y, Nagai N, et al. Preparation of ophthalmic formulations containing cilostazol as an anti-glaucoma agent and improvement in its permeability through the rabbit cornea. J Oleo Sci. 2010;59:423-430.